Table 2 Clinicopathologic associations with PGR variants
From: Progesterone Receptor Gene Variants in Metastatic Estrogen Receptor Positive Breast Cancer
| Factor | Wild-type | Variant | p value |
|---|---|---|---|
| Bone metastasis | |||
| No | 8 (35%) | 15 (65%) | 0.99 |
| Yes | 4 (31%) | 9 (69%) | |
| Brain metastasis | |||
| No | 11 (37%) | 19 (63%) | 0.64 |
| Yes | 1 (17%) | 5 (83%) | |
| Chest wall metastasis | |||
| No | 10 (30%) | 23 (70%) | 0.25 |
| Yes | 2 (67%) | 1 (33%) | |
| Liver metastasis | |||
| No | 11 (34%) | 21 (66%) | 0.99 |
| Yes | 1 (25%) | 3 (75%) | |
| Lung/pleura metastasis | |||
| No | 10 (31%) | 22 (69%) | 0.59 |
| Yes | 2 (50%) | 2 (50%) | |
| Lymph node metastasis | |||
| No | 10 (33%) | 20 (67%) | 0.99 |
| Yes | 2 (33%) | 4 (67%) | |
| Treatment | |||
| Aromatase inhibitor only | 4 (44%) | 5 (56%) | 0.61 |
| Tamoxifen only | 4 (27%) | 11 (73%) | |
| Both | 4 (33%) | 8 (67%) | |
| PR immunohistochemistry | |||
| Negative | 3 (23%) | 10 (77%) | 0.47 |
| Positive | 9 (39%) | 14 (61%) | |
| HER2 status | |||
| Negative | 5 (25%) | 15 (75%) | 0.81 |
| Positive | 2 (25%) | 6 (75%) | |
| Equivocal | 1 (100%) | 0 (0%) | |